Company Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Guardant Health, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
16.67 ^USD	+1.71%		-10.76%	-38.37%

Apr. 15	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
Apr. 03	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	CI

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Number of employees: 1,774

USD in Million	2022	Weight	2023	Weight	Delta
Precision Oncology Testing 91.2 %	392	87.2 %	514	91.2 %	+31.17%
Development Services and Other 8.8 %	57	12.8 %	50	8.8 %	-13.55%

USD in Million	2022	Weight	2023	Weight	Delta
United States 93.4 %	421	93.6 %	527	93.4 %	+25.18%
International 6.6 %	29	6.4 %	37	6.6 %	+29.41%

Managers	Title	Age	Since
Michael Wiley FOU	Founder	48	11-12-31
AmirAli Talasaz FOU	Founder	44	11-12-31
Helmy Eltoukhy CEO	Chief Executive Officer	45	12-12-31
Michael Bell DFI	Director of Finance/CFO	55	21-01-04
Andrew Ament COO	Chief Operating Officer	-	-
Darya Chudova CTO	Chief Tech/Sci/R&D Officer	-	15-07-31
Craig Eagle CTO	Chief Tech/Sci/R&D Officer	57	21-05-02
Kumud Kalia CTO	Chief Tech/Sci/R&D Officer	58	20-01-20
Alex Kleban IRC	Investor Relations Contact	-	-
Christopher Freeman PRN	Corporate Officer/Principal	50	21-05-31

Members of the board	Title	Age	Since
Ian Clark BRD	Director/Board Member	62	16-11-30
Myrtle Potter BRD	Director/Board Member	65	21-10-14
Vijaya Gadde BRD	Director/Board Member	49	20-05-31
Helmy Eltoukhy CEO	Chief Executive Officer	45	12-12-31
Steve Krognes BRD	Director/Board Member	56	22-06-29
AmirAli Talasaz FOU	Founder	44	11-12-31
Musa Tariq BRD	Director/Board Member	41	23-03-05
Meghan Joyce BRD	Director/Board Member	39	21-08-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	121,712,724	116,665,175 ( 95.85 %)	0	95.85 %

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.145 %	11,130,654	9.145 %	230 M $
BlackRock Advisors LLC 8.285 %	10,084,009	8.285 %	208 M $
Deep Track Capital LP 5.751 %	7,000,000	5.751 %	144 M $
Baillie Gifford & Co. 5.077 %	6,178,812	5.077 %	127 M $
Fidelity Management & Research Co. LLC 4.315 %	5,251,349	4.315 %	108 M $
Deep Track Capital LP 4.108 %	5,000,000	4.108 %	103 M $
Capital Research & Management Co. (International Investors) 3.288 %	4,001,803	3.288 %	83 M $
Eventide Asset Management LLC 3.195 %	3,888,146	3.195 %	80 M $
AllianceBernstein LP 3.047 %	3,708,283	3.047 %	77 M $
Temasek Holdings Pte Ltd. 3.018 %	3,673,243	3.018 %	76 M $

Name	Equities	%	Valuation
LUNIT INC. 5.39%	1,550,000	5.39%	67,929,432 $

Guardant Health, Inc.

3100 Hanover Street

94304, Palo Alto

+855 698 8887

http://www.guardanthealth.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.39 USD

Average target price

40.12 USD

Spread / Average Target

+144.81%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
GUARDANT HEALTH, INC.	-38.37%	1.99B
EXACT SCIENCES CORPORATION	-14.19%	11.48B
IOVANCE BIOTHERAPEUTICS, INC.	+44.16%	3.3B
BGI GENOMICS CO., LTD.	-19.90%	2.01B
VERACYTE, INC.	-30.21%	1.42B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+16.18%	1.02B
SEEGENE, INC.	-6.11%	699M
CAREDX, INC	-32.75%	429M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-52.35%	354M
CURIOX BIOSYSTEMS CO., LTD	-3.18%	259M

Bio Diagnostics & Testing